Blog
RSS FeedPosted by Michael Wonder on 08 Jun 2020
NICE publishes appraisal consultation for isatuximab in combination with pomalidomide and dexamethasone for treating patients with relapsed and refractory multiple myeloma
4 June 2020 - The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees ...
Posted by Michael Wonder on 04 Jun 2020
NICE publishes final guidance backing Teva's Ajovy for migraine
4 June 2020 - NICE has now published final guidelines endorsing the NHS use of Teva’s Ajovy (fremanezumab) to prevent ...
Posted by Michael Wonder on 27 May 2020
NICE issues final guidance on NHS use of Bayer's Vitrakvi
27 May 2020 - The NICE has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety ...
Posted by Michael Wonder on 27 May 2020
NICE recommends treatment for type of small-cell lung cancer
27 May 2020 - A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE. ...
Posted by Michael Wonder on 22 May 2020
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
22 May 2020 - Draft guidance published today by NICE recommends atezolizumab for treating people with a type of breast cancer, ...
Posted by Michael Wonder on 28 Apr 2020
NICE U-turn backs Stelara for ulcerative colitis
28 April 2020 - NICE has now issued a positive Final Appraisal Document recommending Janssen's Stelara (ustekinumab) as an option ...
Posted by Michael Wonder on 21 Apr 2020
Andexanet alfa for reversing anticoagulation
21 April 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using andexanet alfa ...
Posted by Michael Wonder on 21 Apr 2020
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund
21 April 2020 - Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after ...
Posted by Michael Wonder on 16 Mar 2020
NICE hits Keytruda with ‘no’ for urothelial cancer
12 March 2020 - NICE has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) ...
Posted by Michael Wonder on 12 Mar 2020
Around 10,000 people could benefit from new migraine drug as NICE says it’s cost-effective
12 March 2020 - NICE has today published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva ...
Posted by Michael Wonder on 05 Mar 2020
NICE pushes Doptelet for pre-surgery liver disease treatment
5 March 2020 - NICE has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - ...
Posted by Michael Wonder on 27 Feb 2020
NICE recommends new ‘chemotherapy-free’ treatment for lymphoma
27 February 2020 - A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been ...
Posted by Michael Wonder on 26 Feb 2020
Polivy struck by NICE ‘no’
26 February 2020 - The National Institute for Health and Care Excellence has announced that it does not recommend Polivy ...
Posted by Michael Wonder on 04 Feb 2020
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
4 February 2020 - NICE has today published the outcome of the appeal against its final draft guidance on erenumab (Aimovig; ...
Posted by Michael Wonder on 03 Feb 2020
Rinvoq NICE approval could benefit 54,000 people
3 February 2020 - The National Institute for Health and Care Excellence has announced a new draft guidance recommending Abbvie’s ...